Trial Profile
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 14 Oct 2020 Status changed from recruiting to discontinued (Low accrual due to COVID-19 pandemic).
- 13 Feb 2020 Planned End Date changed from 15 Feb 2023 to 15 Feb 2021.
- 13 Feb 2020 Planned primary completion date changed from 15 Feb 2020 to 15 Feb 2021.